Half year results from company describing itself as a “world-leading provider of technology-enabled language, content and intellectual property services” RWS Holdings (RWS) included some weaker demand in the current macroeconomic climate and planned investments. However, there looks good reason for some confidence looking ahead and, including with the shares down from above 400p as recently as early this year, we now consider there to be clear value.
Hello Share Managers. This old punter is glad he recently hasn’t held shares in RWS Holdings (RWS). Within the last 12 months, the shares were 680p and today they’re below 400p. But I may consider an investment now as the markdown seems unfair and a tasty recovery could be on the way.
Shares in “technology-enabled language, content and intellectual property services” company RWS Holdings (RWS) are currently, at around 340p, down 27% on the back of acquisition and “Capital Markets Event” announcements. So what’s going on?...
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019 and thus far in 2020 (by net short position %, those in bold not on the list at the start of 2020) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019 and thus far in 2020 (by net short position %, those in bold not on the list at the start of 2020) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
Self-styled “one of the world's leading language, intellectual property support services and localization providers”, RWS Holdings (RWS) has updated including “all RWS divisions remain fully operational” and “in recent days, the group has noted increased demand for services within both our Life Science and Moravia divisions, as our teams help with the clinical trials for new COVID-19 vaccines, translate training material for COVID-19 related antibody testing devices and provide additional services to the group's technology customers, who are recording higher usage of their online communication and social networking platforms. However,”…








